TY - JOUR
T1 - Prescription trends in Japanese advanced Parkinson’s disease patients with non-motor symptoms
T2 - J-FIRST
AU - Nomoto, Masahiro
AU - Tsuboi, Yoshio
AU - Kashihara, Kenichi
AU - Chiu, Shih Wei
AU - Maeda, Tetsuya
AU - Saiki, Hidemoto
AU - Watanabe, Hirohisa
AU - Shimo, Yasushi
AU - Hattori, Nobutaka
AU - Yamaguchi, Takuhiro
N1 - Publisher Copyright:
Copyright: © 2024 Nomoto et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
PY - 2024/10
Y1 - 2024/10
N2 - Background Non-motor symptoms (NMS) are important factors when selecting treatments for patients with advanced Parkinson’s disease (PD). We sought to elucidate the prescribing practices for advanced PD patients with NMS in Japanese clinical practice. Methods We examined the prescription rates and doses of anti-PD drugs, and the use of non-steroidal anti-inflammatory drugs (NSAIDs) in post hoc analyses of a 52-week observational study of 996 PD patients with wearing-off on levodopa-containing therapy and ≥1 NMS. Results Dopamine agonists were the most frequently prescribed drugs combined with levodopa-containing drugs, followed by entacapone, zonisamide, istradefylline, selegiline, and amantadine. The daily dose of levodopa-containing drugs, rotigotine, entacapone, istradefylline, and droxidopa, and the levodopa-equivalent dose increased during the observation period. In a subgroup analysis of patients stratified by NMS status (improved/unchanged/deteriorated), the deteriorated group had higher prescription rates of entacapone and istradefylline, whereas the improved group had higher prescription rates of NSAIDs and zonisamide at Week 52. Prescriptions varied by geographical region for anti-PD drugs and by NMS status for NSAIDs. Conclusions There were significant changes in the prescriptions and dosing of selected anti-PD drugs, especially newer drugs. Anti-PD drug and NSAID prescriptions also varied by changes in NMS status and geographic region.
AB - Background Non-motor symptoms (NMS) are important factors when selecting treatments for patients with advanced Parkinson’s disease (PD). We sought to elucidate the prescribing practices for advanced PD patients with NMS in Japanese clinical practice. Methods We examined the prescription rates and doses of anti-PD drugs, and the use of non-steroidal anti-inflammatory drugs (NSAIDs) in post hoc analyses of a 52-week observational study of 996 PD patients with wearing-off on levodopa-containing therapy and ≥1 NMS. Results Dopamine agonists were the most frequently prescribed drugs combined with levodopa-containing drugs, followed by entacapone, zonisamide, istradefylline, selegiline, and amantadine. The daily dose of levodopa-containing drugs, rotigotine, entacapone, istradefylline, and droxidopa, and the levodopa-equivalent dose increased during the observation period. In a subgroup analysis of patients stratified by NMS status (improved/unchanged/deteriorated), the deteriorated group had higher prescription rates of entacapone and istradefylline, whereas the improved group had higher prescription rates of NSAIDs and zonisamide at Week 52. Prescriptions varied by geographical region for anti-PD drugs and by NMS status for NSAIDs. Conclusions There were significant changes in the prescriptions and dosing of selected anti-PD drugs, especially newer drugs. Anti-PD drug and NSAID prescriptions also varied by changes in NMS status and geographic region.
UR - http://www.scopus.com/inward/record.url?scp=85207434172&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85207434172&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0309297
DO - 10.1371/journal.pone.0309297
M3 - Article
C2 - 39441810
AN - SCOPUS:85207434172
SN - 1932-6203
VL - 19
JO - PloS one
JF - PloS one
IS - 10 October
M1 - e0309297
ER -